DK1620437T3 - 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension - Google Patents
5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertensionInfo
- Publication number
- DK1620437T3 DK1620437T3 DK04728868T DK04728868T DK1620437T3 DK 1620437 T3 DK1620437 T3 DK 1620437T3 DK 04728868 T DK04728868 T DK 04728868T DK 04728868 T DK04728868 T DK 04728868T DK 1620437 T3 DK1620437 T3 DK 1620437T3
- Authority
- DK
- Denmark
- Prior art keywords
- diaminopyrazolo
- hypertension
- treatment
- pyrimidines useful
- pyrimidines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0309780 | 2003-04-29 | ||
GBGB0327748.0A GB0327748D0 (en) | 2003-11-28 | 2003-11-28 | Novel pharmaceuticals |
PCT/IB2004/001433 WO2004096810A1 (en) | 2003-04-29 | 2004-04-22 | 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1620437T3 true DK1620437T3 (da) | 2009-08-24 |
Family
ID=33420887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04728868T DK1620437T3 (da) | 2003-04-29 | 2004-04-22 | 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension |
Country Status (32)
Country | Link |
---|---|
US (2) | US7262192B2 (ko) |
EP (1) | EP1620437B1 (ko) |
JP (2) | JP4015176B2 (ko) |
KR (1) | KR100824193B1 (ko) |
AR (1) | AR044116A1 (ko) |
AT (1) | ATE433978T1 (ko) |
AU (1) | AU2004234158B2 (ko) |
BR (1) | BRPI0409903A (ko) |
CA (1) | CA2523831C (ko) |
CL (1) | CL2004000889A1 (ko) |
CO (1) | CO5640118A2 (ko) |
CR (1) | CR8051A (ko) |
DE (1) | DE602004021585D1 (ko) |
DK (1) | DK1620437T3 (ko) |
EA (1) | EA008596B1 (ko) |
EC (1) | ECSP056130A (ko) |
ES (1) | ES2326119T3 (ko) |
GE (1) | GEP20084329B (ko) |
HK (1) | HK1087108A1 (ko) |
IS (1) | IS8009A (ko) |
MA (1) | MA27771A1 (ko) |
MX (1) | MXPA05011643A (ko) |
NL (1) | NL1026074C2 (ko) |
NO (1) | NO333850B1 (ko) |
NZ (1) | NZ542097A (ko) |
OA (1) | OA13050A (ko) |
PA (1) | PA8601701A1 (ko) |
PE (1) | PE20050462A1 (ko) |
RS (1) | RS20050810A (ko) |
TW (1) | TWI273908B (ko) |
UY (1) | UY28290A1 (ko) |
WO (1) | WO2004096810A1 (ko) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ542097A (en) | 2003-04-29 | 2008-12-24 | Pfizer Ltd | 5,7-Diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
GB0327323D0 (en) * | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
GB0327319D0 (en) * | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
ES2317209T3 (es) | 2004-04-07 | 2009-04-16 | Pfizer Inc. | Pirazolo(4,3-) pirimidinas. |
EP1799664A1 (en) | 2004-09-20 | 2007-06-27 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
JP4958784B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ステアロイル−CoAデサチュラーゼ酵素によって媒介される疾患の処置のための複素環誘導体 |
CA2580855A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
AR051093A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa |
WO2006034338A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase |
US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
JP5043668B2 (ja) | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
EP1809632A2 (en) * | 2004-10-28 | 2007-07-25 | Pharmacia & Upjohn Company LLC | Pyrazolo[4,3-d]pyrimidine derivatives useful as pde-5 inhibitors |
GB0428250D0 (en) * | 2004-12-23 | 2005-01-26 | Novartis Ag | Organic compounds |
JP2008525422A (ja) * | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
US20090005396A1 (en) * | 2005-04-27 | 2009-01-01 | Astrazeneca Ab | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain |
AP2007004219A0 (en) * | 2005-05-12 | 2007-10-31 | Pfizer | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-YL-amino)-1H-pyrazolo[4,3-D] pyrimidine-3-carbonyl]methanesulfonamide |
ATE493413T1 (de) | 2005-05-12 | 2011-01-15 | Pfizer | Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3- |
WO2007130075A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
CA2615946A1 (en) | 2005-07-22 | 2007-02-01 | Sunesis Pharmaceuticals, Inc. | Pyrazolo pyrimidines useful as aurora kinase inhibitors |
WO2007023382A2 (en) * | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
EP1874781B9 (de) * | 2006-04-19 | 2010-09-08 | Boehringer Ingelheim International GmbH | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen |
EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
MX2010003346A (es) | 2007-10-19 | 2010-04-09 | Boehringer Ingelheim Int | Piperazino-dihidrotienopirimidinas sustituidas en heterociclo. |
ATE537175T1 (de) | 2007-10-19 | 2011-12-15 | Boehringer Ingelheim Int | Neue piperazino-dihydrothienopyrimidin-derivate |
WO2009050248A1 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Substituierte piperidino-dihydrothienopyrimidine |
DK2265607T3 (en) | 2008-02-15 | 2017-03-13 | Rigel Pharmaceuticals Inc | PYRIMIDIN-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES |
US8212031B2 (en) * | 2008-03-06 | 2012-07-03 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
WO2009124119A2 (en) * | 2008-04-01 | 2009-10-08 | The Trustes of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
EP2276420B1 (en) | 2008-04-04 | 2021-10-06 | Journey1, Inc. | Device to treat an eye having an epithelium with a defect |
EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
AU2009276420A1 (en) * | 2008-08-01 | 2010-02-04 | Biocryst Pharmaceuticals, Inc. | Piperidine derivatives as JAK3 inhibitors |
CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
WO2011050365A1 (en) | 2009-10-23 | 2011-04-28 | Forsight Labs, Llc | Conformable therapeutic shield for vision and pain |
NO2490635T3 (ko) | 2009-10-23 | 2018-02-03 | ||
US12044905B2 (en) | 2011-04-28 | 2024-07-23 | Journey1 Inc | Contact lenses for refractive correction |
WO2014210186A2 (en) | 2013-06-26 | 2014-12-31 | Nexisvision, Inc. | Contact lenses for refractive correction |
PL2710005T3 (pl) * | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
JO3753B1 (ar) | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
JP6507157B2 (ja) * | 2013-10-07 | 2019-04-24 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | Rhoキナーゼ阻害剤 |
PE20180187A1 (es) | 2015-03-03 | 2018-01-23 | Saniona As | Formulacion de combinacion de tesofensina y betabloqueante |
WO2017103188A1 (en) * | 2015-12-18 | 2017-06-22 | F. Hoffmann-La Roche Ag | Therapeutic compounds, compositions and methods of use thereof |
WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
IL292977A (en) | 2016-09-09 | 2022-07-01 | Incyte Corp | Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy |
US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
WO2018209355A1 (en) * | 2017-05-12 | 2018-11-15 | Innovus Pharmaceuticals, Inc. | Therapeutic methods and compositions |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
US10864205B2 (en) | 2017-12-01 | 2020-12-15 | Innovus Pharmaceuticals, Inc. | Nutritional supplement for improving sexual health in men and women |
US20190167699A1 (en) | 2017-12-01 | 2019-06-06 | Innovus Pharmaceuticals, Inc. | Prostate function support formula |
US10758505B2 (en) | 2017-12-01 | 2020-09-01 | Innovus Pharmaceuticals, Inc. | Therapeutic compositions and methods |
US10500199B2 (en) | 2017-12-01 | 2019-12-10 | Innovus Pharmaceuticals, Inc. | Nutritional supplement for increasing cognitive functions |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
DK3755703T3 (da) | 2018-02-20 | 2022-06-27 | Incyte Corp | N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
ES2973117T3 (es) | 2018-09-25 | 2024-06-18 | Incyte Corp | Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR |
TW202114680A (zh) | 2019-08-06 | 2021-04-16 | 美商英塞特公司 | Hpk1抑制劑之固體形式 |
US20230257376A1 (en) * | 2020-07-14 | 2023-08-17 | Wuhan Ll Science And Technology Development Co., Ltd. | Rock inhibitor, and preparation method therefor and use thereof |
WO2024105159A1 (en) | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3951980A (en) | 1974-05-09 | 1976-04-20 | Stanford Research Institute | 3-Substituted-8-methyl-3,8-diazabicyclo[3.2.1]octanes |
AU516604B2 (en) | 1978-04-03 | 1981-06-11 | Yoshida Kogyo K.K. | Tiltable roller assembly |
AU5661386A (en) | 1985-03-15 | 1986-10-13 | Stirchak, E. | Stereoregular polynucleotide-binding polymers |
US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
US4812590A (en) | 1987-06-25 | 1989-03-14 | Merck & Co., Inc. | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma |
WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
GB8728483D0 (en) | 1987-12-04 | 1988-01-13 | Ciba Geigy Ag | Chemical compounds |
US5091431A (en) * | 1988-02-08 | 1992-02-25 | Schering Corporation | Phosphodiesterase inhibitors |
US5075310A (en) | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
FR2638745B1 (fr) | 1988-11-08 | 1994-01-14 | Synthelabo | Derives de ((n-alkylthioalkyl-methylamino)-2 ethyl)-5 benzothiazepine-1,5 one-4, leur preparation et leur application en therapeutique |
US4994460A (en) | 1989-06-01 | 1991-02-19 | Bristol-Myers Squibb Co. | Agents for treatment of brain ischemia |
JPH03142277A (ja) | 1989-10-30 | 1991-06-18 | Fuji Photo Film Co Ltd | 記録材料 |
US5442044A (en) | 1991-01-04 | 1995-08-15 | Pfizer Inc. | Orally active renin inhibitors |
WO1993001181A1 (en) | 1991-07-03 | 1993-01-21 | The Upjohn Company | Substituted indoles as anti-aids pharmaceuticals |
GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
JP2657760B2 (ja) | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | 4−アミノキナゾリン誘導体およびそれを含有する医薬品 |
GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
US5869486A (en) | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
AU708809B2 (en) | 1995-03-10 | 1999-08-12 | Sanofi Pharmaceuticals, Inc. | 6-aryl pyrazolo{3,4-d}pyrimidin-4-ones and compositions and methods of use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
CZ68199A3 (cs) | 1996-08-28 | 1999-11-17 | Pfizer Inc. | 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob |
DE19644228A1 (de) | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine |
WO1998049166A1 (en) | 1997-04-25 | 1998-11-05 | Pfizer Limited | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
US6184338B1 (en) | 1997-08-27 | 2001-02-06 | Fmc Corporation | Anionic polymerization initiators containing tertiary amine functionality, their chain extended analogues, and processes for using the same |
US6362178B1 (en) | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
DE19752952A1 (de) | 1997-11-28 | 1999-06-02 | Merck Patent Gmbh | Thienopyrimidine |
CA2260499A1 (en) | 1998-01-29 | 1999-07-29 | Sumitomo Pharmaceuticals Company Limited | Pharmaceutical compositions for the treatment of ischemic brain damage |
GB9804426D0 (en) | 1998-03-02 | 1998-04-29 | Pfizer Ltd | Heterocycles |
CN1134442C (zh) | 1998-04-20 | 2004-01-14 | 美国辉瑞有限公司 | 吡唑并嘧啶酮cGMP PDE5抑制剂、其制备方法及用途及中间体 |
DE69911448T2 (de) | 1998-10-23 | 2004-04-08 | Pfizer Inc. | Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen |
EP1171135A4 (en) | 1999-03-10 | 2002-05-15 | Merck & Co Inc | 6-AZAINDOLE COMPOUNDS FOR USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS |
US6465486B1 (en) | 1999-03-12 | 2002-10-15 | Ortho-Mcneil Pharmaceutical, Inc. | Pyridyl/quinolinyl imidazoles |
GB9912415D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
DE19942474A1 (de) | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
PL354675A1 (en) | 1999-09-30 | 2004-02-09 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
PL354982A1 (en) | 1999-09-30 | 2004-03-22 | Neurogen Corporation | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
CN1377356A (zh) | 1999-09-30 | 2002-10-30 | 纽罗杰有限公司 | 亚烷基二胺取代的杂环 |
NZ517324A (en) | 1999-10-11 | 2003-09-26 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-YL)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
US6548509B2 (en) | 1999-10-22 | 2003-04-15 | Neurogen Corporation | 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
HUP0204372A3 (en) | 1999-12-23 | 2004-06-28 | Pfizer Prod Inc | Pharmaceutical compositions providing enhanced drug concentrations |
GB9930570D0 (en) | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
DE60118521T2 (de) | 2000-01-07 | 2006-10-12 | Universitaire Instelling Antwerpen | Purin derivate, ihre herstellung und verwendung |
US20010047013A1 (en) | 2000-03-10 | 2001-11-29 | Fengrui Lang | Process for the preparation of arylamines |
DE10031584A1 (de) | 2000-06-29 | 2002-01-10 | Merck Patent Gmbh | 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine |
EP1176142A1 (en) | 2000-07-28 | 2002-01-30 | Pfizer Inc. | Process for the preparation of pyrazoles |
AU2001272690B2 (en) | 2000-07-28 | 2005-12-08 | Pfizer Inc. | Crystalline therapeutic agent |
EP1176147A1 (en) | 2000-07-28 | 2002-01-30 | Pfizer Limited | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof |
IL154158A0 (en) | 2000-08-11 | 2003-07-31 | Pfizer | Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
EP1341782A2 (en) | 2000-11-20 | 2003-09-10 | Scios Inc. | Inhibitors of p38 kinase |
DE10058662A1 (de) | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Pyrazolo[4,3-d]pyrimidinen |
CA2431077A1 (en) | 2000-12-19 | 2002-06-27 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
DE10104095A1 (de) | 2001-01-31 | 2002-08-01 | Merck Patent Gmbh | Pharmazeutische Formulierung enthaltend Pyrazolo [4,3-d]pyrimidine und Nitrate |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
JP2002255932A (ja) | 2001-03-01 | 2002-09-11 | Katayama Seiyakushiyo:Kk | 3−アルキルアミノアゼチジンの製造方法 |
US20020127593A1 (en) | 2001-03-12 | 2002-09-12 | Regents Of The University Of California | Fluorescence assay for DNA modifying enzymes |
GB0106631D0 (en) | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
US6432957B1 (en) | 2001-06-29 | 2002-08-13 | Kowa Co., Ltd. | Piperazine derivative |
WO2004006867A2 (en) | 2002-03-15 | 2004-01-22 | Wayne State University | 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents |
DE60237425D1 (de) | 2002-03-28 | 2010-10-07 | Univerzita Palackeho V Olomouc | PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung |
US7505971B2 (en) | 2002-06-28 | 2009-03-17 | Hewlett-Packard Development Company, L.P. | Shared drive that provides shared access to editable files in a database |
NZ542097A (en) | 2003-04-29 | 2008-12-24 | Pfizer Ltd | 5,7-Diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension |
-
2004
- 2004-04-22 NZ NZ542097A patent/NZ542097A/en unknown
- 2004-04-22 WO PCT/IB2004/001433 patent/WO2004096810A1/en active Application Filing
- 2004-04-22 ES ES04728868T patent/ES2326119T3/es not_active Expired - Lifetime
- 2004-04-22 EA EA200501333A patent/EA008596B1/ru not_active IP Right Cessation
- 2004-04-22 JP JP2006500346A patent/JP4015176B2/ja not_active Expired - Fee Related
- 2004-04-22 BR BRPI0409903-6A patent/BRPI0409903A/pt not_active IP Right Cessation
- 2004-04-22 AU AU2004234158A patent/AU2004234158B2/en not_active Ceased
- 2004-04-22 KR KR1020057020497A patent/KR100824193B1/ko not_active IP Right Cessation
- 2004-04-22 EP EP04728868A patent/EP1620437B1/en not_active Expired - Lifetime
- 2004-04-22 DE DE602004021585T patent/DE602004021585D1/de not_active Expired - Lifetime
- 2004-04-22 DK DK04728868T patent/DK1620437T3/da active
- 2004-04-22 AT AT04728868T patent/ATE433978T1/de not_active IP Right Cessation
- 2004-04-22 CA CA002523831A patent/CA2523831C/en not_active Expired - Lifetime
- 2004-04-22 MX MXPA05011643A patent/MXPA05011643A/es active IP Right Grant
- 2004-04-22 OA OA1200500306A patent/OA13050A/en unknown
- 2004-04-22 GE GEAP20049033A patent/GEP20084329B/en unknown
- 2004-04-22 RS YUP-2005/0810A patent/RS20050810A/sr unknown
- 2004-04-26 PE PE2004000411A patent/PE20050462A1/es not_active Application Discontinuation
- 2004-04-27 CL CL200400889A patent/CL2004000889A1/es unknown
- 2004-04-27 UY UY28290A patent/UY28290A1/es not_active Application Discontinuation
- 2004-04-28 NL NL1026074A patent/NL1026074C2/nl not_active IP Right Cessation
- 2004-04-28 TW TW093111926A patent/TWI273908B/zh not_active IP Right Cessation
- 2004-04-28 AR ARP040101440A patent/AR044116A1/es unknown
- 2004-04-29 PA PA20048601701A patent/PA8601701A1/es unknown
- 2004-04-29 US US10/834,484 patent/US7262192B2/en not_active Expired - Fee Related
-
2005
- 2005-08-31 IS IS8009A patent/IS8009A/is unknown
- 2005-09-22 NO NO20054404A patent/NO333850B1/no not_active IP Right Cessation
- 2005-10-20 CR CR8051A patent/CR8051A/es not_active Application Discontinuation
- 2005-10-28 MA MA28571A patent/MA27771A1/fr unknown
- 2005-10-28 CO CO05110249A patent/CO5640118A2/es not_active Application Discontinuation
- 2005-10-28 EC EC2005006130A patent/ECSP056130A/es unknown
-
2006
- 2006-06-28 HK HK06107285.3A patent/HK1087108A1/xx not_active IP Right Cessation
-
2007
- 2007-03-16 JP JP2007067736A patent/JP2007217419A/ja active Pending
- 2007-07-31 US US11/831,021 patent/US20070270412A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1620437T3 (da) | 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension | |
CY2014041I1 (el) | 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια | |
DE60330207D1 (de) | le | |
NO20055568D0 (no) | Substituerte 1,4-diazepiner og anvendelser derav | |
IS7520A (is) | Pyrimidínonefnasambönd, samsetningar og aðferðir | |
NL1025404A1 (nl) | Pyrazolo-triazine verbindingen en gebruik daarvan. | |
DK1575597T3 (da) | Anvendelse af rimexolon til behandling af öjentörhed | |
DK2308855T3 (da) | 2,4-Diaminopyrimidinderivater | |
NO20055649D0 (no) | Substituert dihydrokinazolin med antiviale egenskaper | |
DE60209252D1 (de) | Stabilisierte polymerzusammensetzung | |
DE50311534D1 (de) | Gewebeband-einrichtung | |
DK1562932T3 (da) | 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter | |
DE10393374D2 (de) | Zusammensetzung | |
SE0500163L (sv) | Sammansättning | |
DK1373256T3 (da) | CCR5-antagonister, der er nyttige til behandling af AIDS | |
DE60317243D1 (de) | Weiterreichung zwischen domänen | |
DK1561472T3 (da) | Faststofsammensætning | |
DK1492934T3 (da) | Dørenhed | |
FI20020881A (fi) | Iskulaite | |
DK2845594T3 (da) | Anvendelse af dihydroimidazoloner til behandlingen af hunde. | |
NO20044140D0 (no) | New Composition | |
NO20035096L (no) | Konstantstromventil | |
DE60303881D1 (de) | Tintenstrahlaufzeichnungselement | |
DE502004006442D1 (de) | Bauelement | |
FIU20030484U0 (fi) | Patukka-ateria |